Antibody-mediated graft injury: Complement-dependent and complement-independent mechanisms

Current Opinion in Organ Transplantation

Volumn 19, Issue 1, 2014, Pages 33-40

  Valenzuela, Nicole M ^a   McNamara, Jeffrey T ^a   Reed, Elaine F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

antibody mediated rejection; complement; endothelial cell activation; microvascular inflammation

Indexed keywords

EID: 84895902286     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0000000000000040     Document Type: Review

References (70)

1. .Lawrence C, Willicombe M, Brookes PA, et al. Preformed complementactivating low-level donor-specific antibody predicts early antibody-mediated rejection in renal allografts. Transplantation 2013; 95:341-346.
2. Sellares J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012; 12:388-399.
3. Valenzuela NM, Reed EF. Antibodies in transplantation: the effects of HLA and non-HLA antibody binding and mechanisms of injury. Methods Mol Biol 2013; 1034:41-70.
4. Sis B, Jhangri GS, Bunnag S, et al. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant 2009; 9:2312-2323.
5. Berry G, Burke M, Andersen C, et al. Pathology of pulmonary antibodymediated rejection: 2012 update from the Pathology Council of the ISHLT. J Heart Lung Transplant 2013; 32:14-21.
6. Kozlowski T, Andreoni K, Schmitz J, et al. Sinusoidal C4d deposits in liver allografts indicate an antibody-mediated response: diagnostic considerations in the evaluation of liver allografts. Liver Transpl 2012; 18:641-658.
7. Ali S, Ormsby A, Shah V, et al. Significance of complement split product C4d in ABO-compatible liver allograft: diagnosing utility in acute antibody mediated rejection. Transpl Immunol 2012; 26:62-69.
8. O'Leary JG, Klintmalm GB. Impact of donor-specific antibodies on results of liver transplantation. Curr Opin Organ Transplant 2013; 18:279-284.
9. Yan Q, Sui W, Wang B, et al. Expression of MMP-2 and TIMP-1 in renal tissue of patients with chronic active antibody-mediated renal graft rejection. Diagn Pathol 2012; 7:141.
10. Sis B, Jhangri GS, Riopel J, et al. A new diagnostic algorithm for antibodymediated microcirculation inflammation in kidney transplants. Am J Transplant 2012; 12:1168-1179.
11. Papadimitriou JC, Drachenberg CB, Ramos E, et al. Antibody-mediated allograft rejection: morphologic spectrum and serologic correlations in surveillance and for cause biopsies. Transplantation 2013; 95:128-136.
12. de Kort H, Willicombe M, Brookes P, et al. Microcirculation inflammation associates with outcome in renal transplant patients with de novo donorspecific antibodies. Am J Transplant 2013; 13:485-492.
13. Tible M, Loupy A, Vernerey D, et al. Pathologic classification of antibodymediated rejection correlates with donor-specific antibodies and endothelial cell activation. J Heart Lung Transplant 2013; 32:769-776.
14. Lepin EJ, Zhang Q, Zhang X, et al. Phosphorylated S6 ribosomal protein: a novel biomarker of antibody-mediated rejection in heart allografts. Am J Transplant 2006; 6:1560-1571.
15. Sellares J, Reeve J, Loupy A, et al. Molecular diagnosis of antibody-mediated rejection in human kidney transplants. Am J Transplant 2013; 13:971- 983.
16. Lefaucheur C, Loupy A, Vernerey D, et al. Antibody-mediated vascular rejection of kidney allografts: a population-based study. Lancet 2013; 381:313-319.
17. Fishbein GA, Fishbein MC. Morphologic and immunohistochemical findings in antibody-mediated rejection of the cardiac allograft. Hum Immunol 2012; 73:1213-1217.
18. Fedrigo M, Feltrin G, Poli F, et al. Intravascular macrophages in cardiac allograft biopsies for diagnosis of early and late antibody-mediated rejection. J Heart Lung Transplant 2013; 32:404-409.
19. Hidalgo LG, Sellares J, Sis B, et al. Interpreting NK cell transcripts versus T cell transcripts in renal transplant biopsies. Am J Transplant 2012; 12:1180- 1191.
20. Hirohashi T, Chase CM, Della Pelle P, et al. A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody. Am J Transplant 2012; 12:313-321.
21. Kaneku H. Annual literature review of donor-specific HLA antibodies after organ transplantation. Clin Transpl 2011; 311-318.
22. Kittleson MM, Kobashigawa JA. Antibody-mediated rejection. Curr Opin Organ Transplant 2012; 17:551-557.
23. Frank R, Molina MR, Wald JW, et al. Correlation of circulating donor-specific anti-HLA antibodies and presence of C4d in endomyocardial biopsy with heart allograft outcomes: a single-center, retrospective study. J Heart Lung Transplant 2013; 32:410-417.
24. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012; 12:1157-1167.
25. Lobo LJ, Aris RM, Schmitz J, Neuringer IP. Donor-specific antibodies are associated with antibody-mediated rejection, acute cellular rejection, bronchiolitis obliterans syndrome, and cystic fibrosis after lung transplantation. J Heart Lung Transplant 2013; 32:70-77.
26. Ticehurst EH, Molina MR, Frank R, et al. Antibody-mediated rejection in heart transplant patients: long-term follow up of patients with high levels of donordirected anti-DQ antibodies. Clin Transpl 2011; 409-414.
27. Everly MJ, Rebellato LM, Haisch CE, et al. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation 2013; 95:410-417.
28. Kaneku H, O'Leary JG, Banuelos N, et al. De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients. Am J Transplant 2013; 13:1541-1548.
29. Freitas MC, Rebellato LM, Ozawa M, et al. The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes. Transplantation 2013; 95:1113-1139.
30. Jackson AM, Lucas DP, Melancon JK, Desai NM. Clinical relevance and IgG subclass determination of non-HLA antibodies identified using endothelial cell precursors isolated from donor blood. Transplantation 2011; 92: 54-60.
31. Qin Z, Lavingia B, Zou Y, Stastny P. Antibodies against nucleolin in recipients of organ transplants. Transplantation 2011; 92:829-835.
32. Sigdel TK, Li L, Tran TQ, et al. Non-HLA antibodies to immunogenic epitopes predict the evolution of chronic renal allograft injury. J Am Soc Nephrol 2012; 23:750-763.
33. Jackson AM, Lucas DP, Badders JL. A flow cytometric crossmatch test using endothelial precursor cells isolated from peripheral blood. Methods Mol Biol 2013; 1034:319-329.
34. Qin Z, Zou Y, Lavingia B, Stastny P. Identification of endothelial cell surface antigens encoded by genes other than HLA. A combined immunoprecipitation and proteomic approach for the identification of antigens recognized by antibodies against endothelial cells in transplant recipients. Hum Immunol 2013; 74:1445-1452.
35. Giral M, Foucher Y, Dufay A, et al. Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft loss. Am J Transplant 2013; 13:2567-2576.
36. Jackson AM, Kuperman MB, Montgomery RA. Multiple hyperacute rejections in the absence of detectable complement activation in a patient with endothelial cell reactive antibody. Am J Transplant 2012; 12:1643-1649.
37. Breimer ME, Rydberg L, Jackson AM, et al. Multicenter evaluation of a novel endothelial cell crossmatch test in kidney transplantation. Transplantation 2009; 87:549-556.
38. Zitzner JR, Shah S, Jie C, et al. A prospective study evaluating the role of donor-specific antiendothelial crossmatch (XM-ONE assay) in predicting living donor kidney transplant outcome. Hum Immunol 2013; 74:1431- 1436.
39. Saini D, Weber J, Ramachandran S, et al. Alloimmunity-induced autoimmunity as a potential mechanism in the pathogenesis of chronic rejection of human lung allografts. J Heart Lung Transpl 2011; 30:624-631.
40. Golocheikine A, Nath DS, Basha HI, et al. Increased erythrocyte C4D is associated with known alloantibody and autoantibody markers of antibodymediated rejection in human lung transplant recipients. J Heart Lung Transpl 2010; 29:410-416.
41. Lukitsch I, Kehr J, Chaykovska L, et al. Renal ischemia and transplantation predispose to vascular constriction mediated by angiotensin II type 1 receptor- activating antibodies. Transplantation 2012; 94:8-13.
42. Taniguchi M, Rebellato LM, Cai J, et al. Higher risk of kidney graft failure in the presence of anti-Angiotensin II type-1 receptor antibodies. Am J Transplant 2013; 13:2577-2589.
43. Akiyoshi T, Hirohashi T, Alessandrini A, et al. Role of complement and NK cells in antibody mediated rejection. Hum Immunol 2012; 73:1226-1232.
44. AlMahri A, Holgersson J, Alheim M. Detection of complement-fixing and nonfixing antibodies specific for endothelial precursor cells and lymphocytes using flow cytometry. Tissue Antigens 2012; 80:404-415.
45. Bartel G, Wahrmann M, Schwaiger E, et al. Solid phase detection of C4dfixing HLA antibodies to predict rejection in high immunological risk kidney transplant recipients. Transpl Int 2013; 26:121-130.
46. Chen G, Sequeira F, Tyan DB. Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. Hum Immunol 2011; 72:849- 858.
47. Crespo M, Torio A, Mas V, et al. Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter? Transpl Immunol 2013. [Epub ahead of print] 48.
48. Loupy A, Lefaucheur C, Vernerey D, et al. Complement-binding anti-HLA antibodies and kidney-Allograft survival. N Engl J Med 2013; 369:1215- 1226.
49. Lowe D, Higgins R, Zehnder D, Briggs DC. Significant IgG subclass heterogeneity in HLA-specific antibodies: implications for pathogenicity, prognosis, and the rejection response. Hum Immunol 2013; 74:666-672.
50. Bohmig GA, Bartel G, Wahrmann M. Antibodies, isotypes and complement in allograft rejection. Curr Opin Organ Transplant 2008; 13:411-418.
51. Zeevi A, Lunz J, Feingold B, et al. Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibodymediated rejection in heart transplant recipients. J Heart Lung Transplant 2013; 32:98-105.
52. Llorente S, Boix F, Eguia J, et al. C1q-fixing human leukocyte antigen assay in immunized renal patients: correlation between Luminex SAB-C1q and SABIgG. Transplant Proc 2012; 44:2535-2537.
53. Duquesnoy RJ, Marrari M, Jelenik L, et al. Structural aspects of HLA class I epitopes reacting with human monoclonal antibodies in Ig-binding, C1qbinding and lymphocytotoxicity assays. Hum Immunol 2013; 74:1271- 1279.
54. Anthony RM, Wermeling F, Ravetch JV. Novel roles for the IgG Fc glycan. Ann N Y Acad Sci 2012; 1253:170-180.
55. Hayde N, Bao Y, Pullman J, et al. The clinical and genomic significance of donor-specific antibody-positive/C4d-negative and donor-specific antibodynegative/ C4d-negative transplant glomerulopathy. Clin J Am Soc Nephrol 2013. [Epub ahead of print]
56. Jane-Wit D, Manes TD, Yi T, et al. Alloantibody and complement promote T cell-mediated cardiac allograft vasculopathy through Non-canonical NF-kappaB signaling in endothelial cells. Circulation 2013. [Epub ahead of print]
57. Fukami N, Ramachandran S, Narayanan K, et al. Mechanism of accommodation in a sensitized human leukocyte antigen transgenic murine cardiac transplant model. Transplantation 2012; 93:364-372.
58. Jin YP, Fishbein MC, Said JW, et al. Anti-HLA class I antibody-mediated activation of the PI3K/Akt signaling pathway and induction of Bcl-2 and Bcl-xL expression in endothelial cells. Hum Immunol 2004; 65:291-302.
59. Li F, Zhang X, Jin YP, et al. Antibody ligation of human leukocyte antigen class I molecules stimulates migration and proliferation of smooth muscle cells in a focal adhesion kinase-dependent manner. Hum Immunol 2011; 72:1150- 1159.
60. Galvani S, Trayssac M, Auge N, et al. A key role for matrix metalloproteinases and neutral sphingomyelinase-2 in transplant vasculopathy triggered by anti- HLA antibody. Circulation 2011; 124:2725-2734.
61. Bohm A, Flosser A, Ermler S, et al. Factor-Xa-induced mitogenesis and migration require sphingosine kinase activity and S1P formation in human vascular smooth muscle cells. Cardiovasc Res 2013; 99:505-513.
62. Ziegler ME, Jin YP, Young SH, et al. HLA class I-mediated stress fiber formation requires ERK1/2 activation in the absence of an increase in intracellular Ca2 in human aortic endothelial cells. Am J Physiol Cell Physiol 2012; 303:C872-C882.
63. Ziegler ME, Souda P, Jin YP, et al. Characterization of the endothelial cell cytoskeleton following HLA class I ligation. PloS ONE 2012; 7:e29472.
64. Kim S, Coulombe PA. Emerging role for the cytoskeleton as an organizer and regulator of translation. Nat Rev Mol Cell Biol 2010; 11:75-81.
65. Valenzuela NM, Hong L, Shen XD, et al. Blockade of p-selectin is sufficient to reduceMHC I antibody-elicited monocyte recruitment in vitro and in vivo. Am J Transplant 2013; 13:299-311.
66. Yamakuchi M, Kirkiles-Smith NC, Ferlito M, et al. Antibody to human leukocyte antigen triggers endothelial exocytosis. Proc Nat Acad SciU S A 2007; 104:1301-1306.
67. Valenzuela NM, Mulder A, Reed EF. HLA class I antibodies trigger increased adherence of monocytes to endothelial cells by eliciting an increase in endothelial P-selectin and, depending on subclass, by engaging FcgammaRs. J Immunol 2013; 190:6635-6650.
68. Naemi FM, Carter V, Kirby JA, Ali S. Antidonor HLA class I antibodies: pathways to endothelial cell activation and cell-mediated allograft rejection. Transplantation 2013; 96:258-266.
69. Mannam VK, Lewis RE, Cruse JM. The fate of renal allografts hinges on responses of the microvascular endothelium. Exp Mol Pathol 2013; 94:398-411.
70. Cravedi P, Leventhal J, Lakhani P, et al. Immune cell-derived C3a and C5a costimulate human T cell alloimmunity. Am J Transplant 2013; 13:2530-2539.